Insider

Takeda received regulatory acceptance for zasocitinib in moderate-to-severe psoriasis

Takeda said that on September 14, 2026, the FDA and the European Medicines Agency (EMA) accepted applications for zasocitinib (TAK‑279) to treat moderate-to-severe plaque psoriasis, opening the way to further regulatory review.

Verified against 1 archived primary source · SHA-256 recorded Inspect sources & citations ↓
white and red exit sign
Photo by Cory Mogk on Unsplash

Key points

  • The FDA accepted a new New Drug Application (NDA) under a priority review program, and the EMA accepted a new marketing authorization application (MAA), both for zasocitinib in adult moderate-to-severe plaque psoriasis.
  • The drug is intended for patients diagnosed with moderate-to-severe plaque psoriasis who need new systemic therapies.
  • Zasocitinib is an investigational, highly selective TYK2 inhibitor that in laboratory studies showed more than a million‑fold greater selectivity for TYK2 compared with other JAK enzymes.

Regulators approved the drug applications.

The FDA accepted a new New Drug Application (NDA) under a priority review program, and the EMA accepted a new marketing authorization application (MAA), both for zasocitinib in adult moderate-to-severe plaque psoriasis.

Who will benefit

The drug is intended for patients diagnosed with moderate-to-severe plaque psoriasis who need new systemic therapies.

Existing evidence base

Zasocitinib is an investigational, highly selective TYK2 inhibitor that in laboratory studies showed more than a million‑fold greater selectivity for TYK2 compared with other JAK enzymes. The company is already conducting Phase 3 trials in psoriatic arthritis and Phase 2 trials in patients with Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa.

Next steps

The FDA and EMA will now review the submitted applications; the outcomes will determine whether zasocitinib receives approval in the United States and Europe. Simultaneously, Takeda continues to assess the drug’s safety and efficacy in ongoing phase studies, which will inform possible label expansions.

Original sources

  1. 6-K filing, September 14, 2026September 14, 2026SHA-256 of our archived copy 628859f3bd2f…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards